SCHEMBL4062200

SCHEMBL4062200

Fc1ccccc1/C=C/c1nc2ccc(-c3ccco3)cc2o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3R1 P27986 4/20 0.44
PIK3CA P42336 4/20 0.44
METAP2 P50579 1/20 0.41
GPR119 Q8TDV5 2/20 0.40
NFE2L2 Q16236 3/20 0.38
ALOX5 P09917 1/20 0.38
PGR P06401 1/20 0.38
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
PKM P14618 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4062204 1.00 PIK3R1 (0.44) PIK3R1PIK3CAMETAP2GPR119NFE2L2
SCHEMBL4049940 0.92 PIK3R1 (0.46) PIK3R1PIK3CAMETAP2NFE2L2ALOX5
SCHEMBL4049941 0.92 PIK3R1 (0.46) PIK3R1PIK3CAMETAP2NFE2L2ALOX5
SCHEMBL4051602 0.89 NFE2L2 (0.40) PIK3R1PIK3CAGPR119NFE2L2ALOX5
SCHEMBL4051608 0.89 NFE2L2 (0.40) PIK3R1PIK3CAGPR119NFE2L2ALOX5
SCHEMBL4053726 0.84 UTRN (0.47) PIK3R1PIK3CAGPR119ALOX5PGR
SCHEMBL4053724 0.84 UTRN (0.47) PIK3R1PIK3CAGPR119ALOX5PGR
SCHEMBL4054688 0.84 METAP2 (0.44) METAP2GPR119NFE2L2NPC1RAB9A
SCHEMBL4054692 0.84 METAP2 (0.44) METAP2GPR119NFE2L2NPC1RAB9A
SCHEMBL4060472 0.81 PIK3R1 (0.40) PIK3R1PIK3CANFE2L2ALOX5PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B PIK3R1 565/4885PIK3CA 848/4885METAP2 4556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.